|Articles|January 3, 2014

Best of Blog: Most Read Stories of 2013

Our most read stories of 2013.

We hope everyone had a lovely holiday and a very happy new year celebration! We at Applied Clinical Trials want to thank you for your support in 2013, and we're looking forward to sharing an exciting 2014.To help ease back into things following the holiday, we've compiled a look back on our most popular blogs of 2013, in case you might have missed any.

Tips on Writing Risk-Based Monitoring Plans

Future Clinical Trials Are Here and How They May Succeed

How CRO Worldwide Clinical Trials is Approaching eTMF

FDA Updates Current Thinking on Risk-Based Monitoring

Clinical Trials Are Slow at Adopting Change

Future Clinical Trials: How Pharmacies will Transform Clinical Research

The First FDA-Approved Crowdsourced Protocol: An Interview with Tomasz Sablinski, MD, PhD

What Do Risk-Based Monitoring and Patient Engagement Have in Common?

2013 Predictions for Clinical Development

The Gamification of Clinical Trials: What's Next?

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

November 13th, 2026

How Inconsistent Screening Shapes Which Oncology Patients Get Flagged for Trials

In this video interview, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, describes how physician awareness and site-level access drive screening inconsistencies, and why acceptance rates are the same across backgrounds once patients are simply asked.

© JHVEPhoto - © JHVEPhoto - stock.adobe.com

November 13th, 2026

FDA Reportedly Pauses Commissioner’s National Priority Voucher Pilot as Existing Reviews Continue

The agency is still accepting applications but is not reviewing or granting new ones, according to Reuters, while HHS says work under the program is ongoing.

November 13th, 2026

ACT Brief: Zip Code Trial Access, Smaller Biotech APAC Perceptions, and Pimjetmi Tumor Approval

In today’s ACT Brief, we examine how ZIP code shapes trial availability and enrollment, why smaller biotechs hold outdated views of APAC sites, and how FDA approved Pimjetmi for symptomatic tenosynovial giant cell tumor.

November 12th, 2026

Why So Many Patients From Underrepresented Groups Are Never Asked to Join a Trial

In this video interview, Shaalan Beg, MD, MBA, FASCO, chief medical officer at ConcertAI, explains why trial availability, shaped heavily by zip code, is the biggest barrier to enrollment and how access patterns mirror broader healthcare disparities.

November 12th, 2026

Why APAC Clinical Trial Sites Deserve a Second Look: Q&A with James Cheong, Precision for Medicine

In this Q&A, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, discusses why outdated perceptions of APAC sites persist among smaller biotechs, how China’s regulatory reforms have reshaped Phase III startup timelines, and what first-time sponsors need to get right in the region.

November 12th, 2026

ACT Brief: APAC Sponsor Priorities, Continuous Glucose Monitoring Trials, and GLP-1 Eye Warning

In today’s ACT Brief, we examine three priorities for first-time APAC sponsors, how continuous glucose monitoring should be used in diabetes trials, and why FDA is requiring a new eye-related warning across GLP-1 medications.

November 11th, 2026

What Smaller Biotechs Need to Get Right in Their First APAC Phase III Trial

In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, shares three priorities for first-time APAC sponsors: aligning with marketing authorization plans, selecting the right sites, and choosing a CRO with regional experience and KOL networks.

How regulatory guidance, blinding, study-provisioned devices, and ePRO integration shape reliable CGM data collection in diabetes clinical trials. Credit: Stock.Adobe.com/martenaba

November 11th, 2026

Continuous Glucose Monitoring in Diabetes Clinical Trials: Endpoints, Regulatory Guidance, and Operational Best Practices

FDA and EMA expectations shape how sponsors use CGM in diabetes trials, from blinding and study-provisioned devices to data integrity and ePRO integration.

Best of Blog: Most Read Stories of 2013

Related to this article

Trending on Applied Clinical Trials Online

Why So Many Patients From Underrepresented Groups Are Never Asked to Join a Trial

Why APAC Clinical Trial Sites Deserve a Second Look: Q&A with James Cheong, Precision for Medicine

FDA Reportedly Pauses Commissioner’s National Priority Voucher Pilot as Existing Reviews Continue

Continuous Glucose Monitoring in Diabetes Clinical Trials: Endpoints, Regulatory Guidance, and Operational Best Practices

What Smaller Biotechs Need to Get Right in Their First APAC Phase III Trial